Company Profile

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.

Employees

Sector

Biotechnology & Medical Research

More about the company

06-14	Menarini Group and Stemline Therapeutics, Inc. Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis	CI
05-28	The Menarini Group and Stemline Therapeutics, Inc. Presents New Data From The Phase 1b/2 ELEVATE Study Of Elacestrant In Combination With Capivasertib In Patients With ER+, HER2- Metastatic Breast Cancer	CI
05-25	Menarini Group Announces New Data At the American Society of Clinical Oncology 2026 Annual Meeting	CI
12-08	Menarini Group and Stemline Therapeutics, Inc. Presents Elacestrant Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer at the 2025 San Antonio Breast Cancer Symposium	CI
11-24	Menarini Group and Stemline Therapeutics, Inc. to Present New Data Related to ELZONRIS	CI
25-03-20	Menarini Group and Stemline Therapeutics Inc. Announce Collaboration with VisualDx to Aid in Identifying People Who May Have Blastic Plasmacytoid Dendritic Cell Neoplasm	CI
24-12-11	Menarini Group Along with Stemline Therapeutics, Inc and Medsir Present the Phase III Study Adela	CI
23-12-11	Menarini Group Presents Initial Safety and Efficacy Data from Phase 1B/2 Elevate and Electra Combination Studies of Orserdu® (Elacestrant) in Patients with Er+, Her2- Metastatic Breast Cancer At the 2023 San Antonio Breast Cancer Symposium	CI
23-12-08	Menarini Group and Stemline Therapeutics, Inc. Presents New Progression-Free Survival Data from Emerald Clinical Study of Orserdu (Elacestrant) in Clinically Relevant Subgroups of Patients with Esr1 Mutations At Sabcs 2023	CI
23-11-20	The Menarini Group and Stemline Therapeutics, Inc. to Present New Data Related to ORSerDU	CI
23-10-30	Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group	CI
23-09-20	European Commission Approves Menarini Group?s ORSERDU (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation	CI
23-05-25	The Menarini Group and Stemline Therapeutics Announce Results from A New Analysis of the Pivotal EMERALD Clinical Study	CI

20-12-17	Stemline Therapeutics : The Menarini Group received the coveted XV Transatlantic Award from the American Chamber of Commerce in Italy	AQ
20-06-10	STEMLINE THERAPEUTICS INC : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
20-05-11	STEMLINE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
20-05-05	Stemline Therapeutics : The Menarini Group signs the agreement for the acquisition of Stemline Therapeutics for a maximum consideration of $ 677 million	AQ
20-05-04	STEMLINE THERAPEUTICS INC : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ

19-01-16	Dow Jones Industrial Average : Les valeurs à suivre à Wall Street
19-01-16	USA-Les valeurs à suivre à Wall Street (actualisé)

Manager	Title	Age	Since
Ivan Bergstein CEO	Chief Executive Officer	60	-
David Gionco DFI	Director of Finance/CFO	65	2014-01-15
Jeffrey Levitt CMP	Compliance Officer	-	2021-03-31

Date	Insider	Type	Main position	Quantity	% Market Cap.
20-06-09	Ivan Bergstein	Free	Chief Executive Officer	3,872,092	7.3739%
20-06-09	Kenneth Zuerblis	Tender	Director	118,121	0.2249%
20-06-09	Kenneth Hoberman	Free	Chief Operating Officer	2,043,410	3.8914%

Stemline Therapeutics, Inc. Stock

Stocks

US85858C1071

Biotechnology & Medical Research

Latest news : Stemline Therapeutics, Inc.

Press Releases: Stemline Therapeutics, Inc.

News in other languages: Stemline Therapeutics, Inc.

Managers and Directors: Stemline Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
STEMLINE THERAPEUTICS, INC.	-.--%	-.--%	-	-	570M
ARGENX SE	-2.86%	-0.26%	+51.45%	+110.98%	56.42B
WUXI APPTEC CO., LTD.	-0.34%	+3.51%	+45.55%	+40.16%	44.54B
BIONTECH SE	+0.29%	+6.20%	-14.80%	-19.65%	22.9B
INSMED INCORPORATED	-0.40%	+3.49%	-1.29%	+387.06%	21.21B
WUXI BIOLOGICS (CAYMAN) INC.	-2.33%	+0.87%	+13.96%	-36.35%	16.4B
GENMAB A/S	-1.54%	-1.06%	+7.63%	-39.28%	15.4B
EXELIXIS, INC.	-0.24%	+2.44%	+27.43%	+177.49%	13.35B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.14%	+7.43%	+16.71%	-	12.36B
PHARMAESSENTIA CORPORATION	+0.32%	+2.81%	+96.37%	+213.49%	11.15B
Average	-0.78%	+1.51%	+27.00%	+104.24%	23.75B
Weighted average by Cap.	-1.16%	+1.93%	+30.69%	+96.14%